摘要
Dear Editor,Recombinant tissue plasminogen activator（rt-PA）remains the only proven therapy for acute ischemic stroke patients who meet the selection criteria for treatment[1–3].A small number of studies have investigated the efficacy of rt-PA for elderly stroke patients in Japanese and Caucasian populations[4,5].According to the American Heart Association/American Stroke Association Guidelines,
Dear Editor,Recombinant tissue plasminogen activator（rt-PA）remains the only proven therapy for acute ischemic stroke patients who meet the selection criteria for treatment[1–3].A small number of studies have investigated the efficacy of rt-PA for elderly stroke patients in Japanese and Caucasian populations[4,5].According to the American Heart Association/American Stroke Association Guidelines,
基金
the Shanghai Municipal Commission of Health and Family Planning for its grant support for the establishment and implementation of the stroke management model in Shanghai,China
